ARTICLE | Emerging Company Profile

AgomAb: antibodies driving tissue regeneration and recovery

Emerging Company Profile: argenx spinout AgomAb raises $74M series B to complete clinical POC for lead mAb and grow pipeline

March 11, 2021 10:33 PM UTC

AgomAb parlayed what began as a cancer drug discovery partnership into an antibody program that could drive tissue regeneration and organ recovery. 

On Wednesday, the Belgian biotech raised $74 million in a series B round led by Redmile Group and joined by Cormorant Asset Management, setting the stage for a potential near-term IPO. All of the company’s existing investors also participated. ...